Pharmaceutical major Lupin on Tuesday reported a 55% year-on-year rise in consolidated net profit to ₹882 crore for the quarter ended June. The total revenue grew by 41% to ₹4,439 crore. Sales from active pharmaceutical ingredients declined 12.4% to ₹286.9 crore. This was a record quarter driven by robust growth across the US, India, and Japan, Lupin stated.